BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37336145)

  • 1. Generation of TWO G51D SNCA missense mutation iPSC lines (CRICKi011-A, CRICKi012-A) from two individuals at risk of Parkinson's disease.
    Devito LG; Zanjani ZS; Evans JR; Scardamaglia A; Houlden H; Gandhi S; Healy L
    Stem Cell Res; 2023 Sep; 71():103134. PubMed ID: 37336145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation.
    Kiely AP; Ling H; Asi YT; Kara E; Proukakis C; Schapira AH; Morris HR; Roberts HC; Lubbe S; Limousin P; Lewis PA; Lees AJ; Quinn N; Hardy J; Love S; Revesz T; Houlden H; Holton JL
    Mol Neurodegener; 2015 Aug; 10():41. PubMed ID: 26306801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of an induced pluripotent stem cell line (EURACi014-A) from a Parkinson's disease patient with an A53T mutation in the SNCA gene by an integration-free reprogramming method.
    Gilmozzi V; Gentile G; Riekschnitz DA; Volpato CB; Di Segni M; Silipigni R; Pramstaller PP; Hicks AA; Pichler I; Zanon A
    Stem Cell Res; 2022 Apr; 60():102713. PubMed ID: 35189566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The G51D SNCA mutation generates a slowly progressive α-synuclein strain in early-onset Parkinson's disease.
    Lau HHC; Martinez-Valbuena I; So RWL; Mehra S; Silver NRG; Mao A; Stuart E; Schmitt-Ulms C; Hyman BT; Ingelsson M; Kovacs GG; Watts JC
    Acta Neuropathol Commun; 2023 May; 11(1):72. PubMed ID: 37138318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of gene-corrected iPSC line from Parkinson's disease patient iPSC line with alpha-SNCA A53T mutation.
    Lee SY; Jeong S; Kim J; Chung SK
    Stem Cell Res; 2018 Jul; 30():145-149. PubMed ID: 29906669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a human induced pluripotent stem cell line derived from a Parkinson's disease patient carrying SNCA duplication.
    Suzuki H; Egawa N; Kondo T; Imamura K; Enami T; Tsukita K; Suga M; Shibukawa R; Okanishi Y; Uchiyama T; Inoue H; Takahashi R
    Stem Cell Res; 2020 May; 45():101828. PubMed ID: 32413791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains.
    Mokretar K; Pease D; Taanman JW; Soenmez A; Ejaz A; Lashley T; Ling H; Gentleman S; Houlden H; Holton JL; Schapira AHV; Nacheva E; Proukakis C
    Brain; 2018 Aug; 141(8):2419-2431. PubMed ID: 29917054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of an induced pluripotent stem cell line (CSC-32) from a patient with Parkinson's disease carrying a heterozygous variation p.A53T in the SNCA gene.
    Azevedo C; Chumarina M; Serafimova E; Goldwurm S; Collin A; Roybon L; Savchenko E; Pomeshchik Y
    Stem Cell Res; 2020 Mar; 43():101694. PubMed ID: 31954327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of two iPS cell lines (HIHDNDi001-A and HIHDNDi001-B) from a Parkinson's disease patient carrying the heterozygous p.A30P mutation in SNCA.
    Barbuti PA; Santos BFR; Dording CM; Cruciani G; Massart F; Hummel A; Krüger R
    Stem Cell Res; 2020 Oct; 48():101951. PubMed ID: 32798915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?
    Kiely AP; Asi YT; Kara E; Limousin P; Ling H; Lewis P; Proukakis C; Quinn N; Lees AJ; Hardy J; Revesz T; Houlden H; Holton JL
    Acta Neuropathol; 2013 May; 125(5):753-69. PubMed ID: 23404372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
    Rutherford NJ; Moore BD; Golde TE; Giasson BI
    J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of three clones (JUCGRMi002-A, B, C) of induced pluripotent stem cells from a Parkinson's disease patient with SNCA duplication.
    Ishikawa KI; Shiga T; Yoshino H; Nishioka K; Hattori N; Akamatsu W
    Stem Cell Res; 2024 Feb; 74():103296. PubMed ID: 38154385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.
    Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R
    Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on novel familial forms of Parkinson's disease and multiple system atrophy.
    Fujioka S; Ogaki K; Tacik PM; Uitti RJ; Ross OA; Wszolek ZK
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S29-34. PubMed ID: 24262183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing.
    Perez-Rodriguez D; Kalyva M; Leija-Salazar M; Lashley T; Tarabichi M; Chelban V; Gentleman S; Schottlaender L; Franklin H; Vasmatzis G; Houlden H; Schapira AHV; Warner TT; Holton JL; Jaunmuktane Z; Proukakis C
    Acta Neuropathol Commun; 2019 Dec; 7(1):219. PubMed ID: 31870437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease and multiple system atrophy patient iPSC-derived oligodendrocytes exhibit alpha-synuclein-induced changes in maturation and immune reactive properties.
    Azevedo C; Teku G; Pomeshchik Y; Reyes JF; Chumarina M; Russ K; Savchenko E; Hammarberg A; Lamas NJ; Collin A; Gouras GK; Klementieva O; Hallbeck M; Taipa R; Vihinen M; Roybon L
    Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2111405119. PubMed ID: 35294277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications.
    Iannielli A; Luoni M; Giannelli SG; Ferese R; Ordazzo G; Fossati M; Raimondi A; Opazo F; Corti O; Prehn JHM; Gambardella S; Melki R; Broccoli V
    Cell Death Dis; 2022 Oct; 13(10):881. PubMed ID: 36261424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.
    Singh Dolt K; Hammachi F; Kunath T
    Brain Pathol; 2017 Jul; 27(4):545-551. PubMed ID: 28585381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of Synucleinopathies.
    Nussbaum RL
    Cold Spring Harb Perspect Med; 2018 Jun; 8(6):. PubMed ID: 28213435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus.
    Devine MJ; Ryten M; Vodicka P; Thomson AJ; Burdon T; Houlden H; Cavaleri F; Nagano M; Drummond NJ; Taanman JW; Schapira AH; Gwinn K; Hardy J; Lewis PA; Kunath T
    Nat Commun; 2011 Aug; 2():440. PubMed ID: 21863007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.